超越靶病灶:纵向AI全身体积分在转移性黑色素瘤中的预后价值
结果显示,中期和晚期TMTV、TLG升高与更差OS显著相关,晚期指标在多变量分析中独立于LDH、AJCC分期和ECOG状态;传统代谢反应标准仅显示无统计学显著的趋势。
要点
- AI全身体积分在全部检查中可行,晚期TMTV和TLG升高独立预测更差OS。
- 基线TMTV和TLG与OS无显著关联,中期和晚期体积分与OS显著相关。
- 传统代谢反应标准在中期和晚期均仅显示无统计学显著的趋势。
核心结论
- AI纵向全身体积分TMTV和TLG可为接受免疫治疗的转移性黑色素瘤患者提供独立预后信息。
- 晚期随访影像的体积分与OS关联稳健,可能优于传统反应标准。
研究设计与样本
- 单中心前瞻性队列纳入43例不可切除转移性黑色素瘤患者,均接受ICI治疗。
- 采用Kaplan-Meier、log-rank检验和Cox回归分析OS,多变量模型纳入LDH、AJCC分期和ECOG状态。
主要发现
- 中位随访97.8个月(95%CI 90.1-134.5个月),AI全身体积分在所有检查中可行。
- 单变量Cox分析:基线TMTV和TLG与OS无显著关联;中期TMTV和TLG均p=0.04;晚期TMTV p=0.03、TLG p=0.02。
- 中位数二分法:基线TLG log-rank p=0.021、TMTV p=0.10;中期TMTV p=0.01、TLG p=0.04;晚期两者均p=0.009。
- 多变量分析:晚期TMTV和TLG升高与更差OS独立相关,LDH升高亦独立相关,ECOG评分较低独立预测更好生存。
- 传统代谢反应标准(EORTC、PERCIST、PERCIMT、imPERCIST5、iPERCIST)在中期和晚期均显示反应者OS更长的无统计学显著趋势,以PERCIMT最明显。
关键数值与推荐
- 中位随访97.8个月(95%CI 90.1-134.5个月)。
- 单变量Cox:中期TMTV和TLG均p=0.04;晚期TMTV p=0.03、TLG p=0.02。
- 中位数二分log-rank:基线TLG p=0.021、TMTV p=0.10;中期TMTV p=0.01、TLG p=0.04;晚期两者均p=0.009。
临床怎么用
- 可在免疫治疗期间用AI全身体积分纵向监测肿瘤负荷,辅助风险分层。
- 晚期PET/CT的TMTV和TLG升高提示预后较差,可支持治疗监测决策。
局限性
- 样本量仅43例,结论需更大队列验证。
- 传统代谢反应标准与OS的关联未达统计学显著,仅显示趋势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the prognostic value of an artificial intelligence (AI)-based semi-automated tool for longitudinal whole-body quantification of total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) on [1⁸F]FDG PET/CT in patients with metastatic melanoma undergoing immune checkpoint inhibitor (ICI) therapy, and to assess its prognostic relevance alongside established PET-based metabolic response criteria. METHODS: Forty-three patients with unresectable metastatic melanoma treated with ICIs underwent [1⁸F]FDG PET/CT at baseline (n = 43), after two cycles (interim; n = 41), and after four cycles of therapy (late; n = 43). Whole-body tumor segmentation was performed using a previously validated AI-based framework combining ensemble unsupervised segmentation and deep representation learning, followed by expert review. TMTV and TLG were calculated for each time point. Overall survival (OS) was analyzed using Kaplan-Meier estimates, log-rank tests, and Cox proportional hazards regression. Multivariable models included LDH, AJCC stage, and ECOG performance status. Metabolic response was additionally assessed using EORTC, PERCIST, PERCIMT, imPERCIST5, and iPERCIST criteria. RESULTS: Median follow up [95% CI] of the patient cohort from the date of baseline PET/CT was 97.8 months [90.1-134.5 months]. Automated whole-body segmentation and volumetric quantification were feasible in all examinations. In univariable Cox analysis, baseline TMTV and TLG showed non-significant associations with OS. At interim and late PET/CT, higher TMTV and TLG were significantly associated with worse OS (interim: p = 0.04 for both; late: p = 0.03 for TMTV, p = 0.02 for TLG). Median-based dichotomization confirmed shorter OS in patients with elevated volumetric parameters with a statistically significant association for TLG (logrank p = 0.021) and a trend toward significance for TMTV (logrank p = 0.10) at baseline. At interim imaging, both TMTV (logrank p = 0.01) and TLG (logrank p = 0.04) were significantly associated with worse OS, with the strongest associations observed at late follow-up (both logrank p = 0.009). In multivariable analysis, elevated late TMTV and TLG remained independently associated with poorer OS, alongside increased LDH, whereas lower ECOG performance status independently predicted improved survival. Among the applied metabolic response criteria, at both interim and late PET/CT, survival curves demonstrated a non-significant trend toward longer OS in responders (CMR + PMR) compared with non-responders (SMD + PMD), with this trend being most pronounced for PERCIMT. CONCLUSION: AI-based longitudinal whole-body quantification of TMTV and TLG on [1⁸F]FDG PET/CT appears to provide independent prognostic information in metastatic melanoma patients undergoing immunotherapy. In particular, volumetric PET metrics derived from late follow-up imaging demonstrate robust association with OS and may outperform conventional response criteria. AI-driven whole-body tumor burden assessment may enhance objective risk stratification and support treatment monitoring in the era of immunotherapy.
引用
- Sachpekidis C, Vagenas TP, Müller M, et al. Beyond target lesions: Prognostic value of longitudinal AI-derived whole-body [1⁸F]FDG PET/CT metrics in metastatic melanoma. Eur J Nucl Med Mol Imaging. 2026. PMID: 42189229. doi:10.1007/s00259-026-07915-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。